491 related articles for article (PubMed ID: 31748961)
1. The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis.
Zheng SY; Cui HJ; Duan H; Peng YM; Li Q; Sun CY; Zhang JY; Shen W; Zhang X; Tan K; Jiang X
Clin Transl Oncol; 2020 Jul; 22(7):1146-1154. PubMed ID: 31748961
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis.
Zhang R; Zhu J; Liu Y; Xin Y; Wang Y; Niu K; Wei H
Medicine (Baltimore); 2021 Mar; 100(10):e19713. PubMed ID: 33725808
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis.
Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
Int Immunopharmacol; 2021 Jul; 96():107594. PubMed ID: 33798808
[TBL] [Abstract][Full Text] [Related]
4. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
5. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
6. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang Y; Luo H; Zheng XL; Ge H
Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.
Wu LG; Zhou DN; Wang T; Ma JZ; Sui H; Deng WL
Medicine (Baltimore); 2021 Mar; 100(12):e25145. PubMed ID: 33761681
[TBL] [Abstract][Full Text] [Related]
8. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.
Chen W; Li L; Cheng S; Yu J
Dis Markers; 2022; 2022():2631852. PubMed ID: 36061356
[TBL] [Abstract][Full Text] [Related]
9. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer.
Bozcuk H; Artaç M; Mutlu H; Sever Ö; Yıldırım M
J Oncol Pharm Pract; 2021 Mar; 27(2):405-413. PubMed ID: 33040676
[TBL] [Abstract][Full Text] [Related]
13. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S
Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis.
Meng LF; Huang JF; Luo PH; Huang SX; Wang HL
Invest New Drugs; 2022 Aug; 40(4):810-817. PubMed ID: 35412172
[TBL] [Abstract][Full Text] [Related]
16. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang H; Li X; Huang X; Li J; Ma H; Zeng R
J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis.
Xu H; Ming P; Zhao Z; Zhao N; Zhou D; Tang X; Cao D
Integr Cancer Ther; 2023; 22():15347354231164584. PubMed ID: 36998207
[TBL] [Abstract][Full Text] [Related]
18. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
19. Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis.
Wang J; Cao L; Xu S
Int Immunopharmacol; 2020 Nov; 88():106907. PubMed ID: 33182031
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]